珀金埃尔默

Revvity Inc. Executives Make Significant Stock Trades Amid Market Volatility

Revvity's 15min Chart: Bollinger Bands Narrowing, KDJ Death Cross Triggered

Revvity

Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026

Revvity Unveils Revolutionary Discovery Platforms at SLAS2026

Revvity's Senior Vice President Buys and Sells Shares on Feb 2.

Catalyst<ul> <li>Most analysts rate RVTY Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>Bearish signals are obviously dominant (3 bearish vs 0 bullish).</li> <li>At least one major firm maintains a Neutral rating, citing valuation concerns.</li> <li>Fund flows show negative overall trend with Extra-large and Large orders trending negatively.</li></ul>

Key Factors

Revvity reported Q4 revenue of $772 million, representing 6% year-over-year growth and 4% organic growth, with adjusted EPS of $1.70 exceeding expectations.Revvity executives conducted multiple share purchases and sales in early February 2026, including significant transactions by Senior Vice President Joel S. Goldberg and CEO Prahlad R. Singh.Revvity unveiled new discovery platforms at SLAS2026, including Opera Phenix OptIQ, EnVision Nexus One, and AssayMate, designed to accelerate drug discovery workflows using automation, AI, and trusted assay technologies.

RVTY News